September 23, 2021 11:18 AM EDTUpdated 06:08 PM
FDA+

FDA's can­cer drug ad­vi­sors will re­view 2 more dan­gling ac­cel­er­at­ed ap­provals for mul­ti­ple myelo­ma, leukemia

Zachary Brennan

Senior Editor

In an at­tempt to get its house of ac­cel­er­at­ed ap­provals in or­der, the FDA is hold­ing its sec­ond ad­comm of 2021 to re­view can­cer drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times